AOBiome

About:

AOBiome is a life sciences company that focuses on transforming human health.

Website: https://www.aobiome.com/

Twitter/X: aobiome

Top Investors: iCarbonX, Hedgewood, Wakestream Ventures

Description:

AOBiome is a life sciences company that focuses on transforming human health by developing microbiome-based therapies for inflammatory conditions. The company's portfolio includes multiple clinical-stage programs; a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis), a Phase 2a study to treat patients with adult eczema (atopic dermatitis), a Phase 2 study for the prevention of episodic migraines, and a Phase 1b/2a clinical trial for the treatment of allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. Its product candidates harness a single strain of class-defining, auto-regulating Ammonia Oxidizing Bacteria (AOB), a human commensal, enabling healthcare practitioners to produce well-understood and well-characterized biochemical compound that are critical to human health. AOBiome was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Total Funding Amount:

$38.7M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2013-01-01

Contact Email:

info(AT)aobiome.com

Founders:

David Whitlock, Jamie Heywood, Spiros Jamas

Number of Employees:

11-50

Last Funding Date:

2017-01-05

IPO Status:

Private

Industries:

© 2025 bioDAO.ai